この論文をさがす
説明
<jats:p>(Abstracted from <jats:italic toggle="yes">N Engl J Med</jats:italic> 2019;381:1929–1939)</jats:p> <jats:p>The National Comprehensive Cancer Network recommends secondary cytoreduction for ovarian cancer patients with recurrent disease who have received no treatment for a period of 6 months following a complete response from prior chemotherapy. Retrospective reviews and meta-analyses have shown the most benefit from this operation in those with platinum-sensitive disease and those with little or no postoperative residual disease.</jats:p>
収録刊行物
-
- Obstetrical & Gynecological Survey
-
Obstetrical & Gynecological Survey 75 165-166, 2019-11-14
Ovid Technologies (Wolters Kluwer Health)
- Tweet
キーワード
- Reoperation
- Paclitaxel
- 610
- Medical and Health Sciences
- Carboplatin
- Rare Diseases
- Clinical Research
- Neoplasms
- General & Internal Medicine
- Antineoplastic Combined Chemotherapy Protocols
- Humans
- Neoplasms, Glandular and Epithelial
- Cancer
- Aged
- Ovarian Neoplasms
- Rehabilitation
- Evaluation of treatments and therapeutic interventions
- Glandular and Epithelial
- Cytoreduction Surgical Procedures
- Middle Aged
- Combined Modality Therapy
- Survival Analysis
- Ovarian Cancer
- Bevacizumab
- Neoplasm Recurrence
- Local
- Quality of Life
- Female
- Patient Safety
- Neoplasm Recurrence, Local
- 6.4 Surgery